An approved therapy for multiple sclerosis (MS), called Gilenya (fingolimod), was effective at treating a man who had…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
A common over-the-counter painkiller induced two allergic reactions — one of them leading to angioedema, and another to skin…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
A man who had been treated with the blood pressure medication losartan for 20 years experienced sudden angioedema after…
Takhzyro (lanadelumab) has been approved in Japan to prevent acute swelling attacks in people, 12 and older, with…
Donidalorsen significantly reduced swelling attacks and improved quality of life in people with hereditary angioedema (HAE) treated in…
Astria Therapeutics is gearing up to request permission for clinical testing in the U.S. of STAR-0215, its experimental therapy…
KalVista Pharmaceuticals has launched a Phase 3 trial, called KONFIDENT, to test the safety and effectiveness of KVD900,…
Special care must be taken with surgeries under general anesthesia in people with hereditary angioedema (HAE) to avoid dangerous…
People with hereditary angioedema (HAE) commonly have histories of cancer, which raises the possibility that it might predispose a…